Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

He suggested following few must-read papers on X:

1.”HIPEC Extends Survival in Recurrent Ovarian Cancer.

The CHIPOR trial shows adding HIPEC to cytoreductive surgery improves survival:

• 54.3 months OS with HIPEC vs. 45.8 months without.
• Higher grade ≥3 toxicities.”

Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.

Authors: Prof Jean-Marc Classe, et al.

2.”Adolescents and young adults (AYA) Cancer: Global Trends & Challenges.

In 2022, 1.3M adolescents & young adults (15–39) faced cancer, with disparities by region:

• 57% fatality in low-income settings vs. 12% in high-income settings.
• A projected 102% increase in low HDI countries by 2050.

Prioritize global equity in cancer care.”

The current and future global burden of cancer among adolescents and young adults: a population-based study.

Authors: Taylor Hughes, et al.

3.”RADICALS-HD: Adding ADT to postop RT in prostate cancer shows no MFS improvement. Long-term outcomes remain favorable, even without ADT. High-risk cases need focus!

A total of 492 participants due for radiotherapy (RT) after previous prostate cancer surgery were allocated to RT alone, RT with 6 mo of hormone therapy, or RT with 24 mo of hormone therapy. No meaningful differences were seen in long-term outcomes between the three groups.”

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD.

Authors: Chris C Parker, et al.

4.”Mechanisms of resistance to PARP inhibitors in advanced prostate cancer with BRCA2/PALB2 alterations: Reversion mutations emerge within 16 weeks. These associate with disease progression and survival.”

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Authors: George Seed, et al.

5.”New research reveals an ‘obesogenic memory’ in adipose tissue driven by epigenetic changes, fueling rebound weight gain after dieting.

A key to ending the yo-yo effect? “

Adipose tissue retains an epigenetic memory of obesity after weight loss.

Authors: Laura C. Hinte, et al.

For latest updates, follow OncoDaily.